Physician profile
Osman Mir
NPI 1821273590
$9,099.84
in general payments reported to CMS, 2019-2025
24 companies · $2,357 in 2025
The $2,357 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $376 · 2020: $1,309 · 2021: $651 · 2022: $303 · 2023: $841 · 2024: $3,262 · 2025: $2,357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,665 · Travel and Lodging: $2,045 · Consulting Fee: $1,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,665.17 |
| Travel and Lodging | $2,045.35 |
| Consulting Fee | $1,750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Imperative Care, INC | $3,331.99 | 2021-2025 | Zoom 88-T Large Distal Platform, Symphony Catheter, Zoom 7x Catheter |
| Cordis US Corp. | $1,251.87 | 2024 | Angioguard, Ncraft Aaa Stent Graft System |
| Microvention, INC. | $1,247.78 | 2020-2024 | Web Aneurysm Embolization System, Sofia 6f-131cm Str, Hydrosoft Advanced |
| Balt USA, LLC | $795.26 | 2020-2025 | Optima Coil System |
| Medtronic, INC. | $569.81 | 2021-2025 | Pipeline, Spiderfx |
| Stryker Corporation | $439.65 | 2019-2024 | Evolve, Neuroform Atlas |
| Medtronic USA, INC. | $223.24 | 2019-2020 | |
| Depuy Synthes Sales INC. | $215.02 | 2019-2023 | Emboguard |
| Rapid Medical LTD | $209.88 | 2023 | Comaneci 17, Tigertriever 17 Revascularization Device |
| Phenox INC. | $202.99 | 2020-2021 | |
| Route 92 Medical, INC. | $149.87 | 2021 | |
| Merz Pharmaceuticals, LLC | $85.72 | 2022 | |
| Ucb, INC. | $75.78 | 2019 | |
| Acadia Pharmaceuticals INC | $53.57 | 2025 | Nuplazid |
| Qapel Medical INC | $44.80 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $40.04 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $36.59 | 2025 | Austedo Xr |
| Janssen Biotech, INC. | $32.67 | 2025 | |
| Abbott Laboratories | $25.45 | 2025 | Infinity |
| Amgen INC. | $24.50 | 2025 | Uplizna |
| Microtransponder, INC. | $19.79 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $13.61 | 2019 | |
| Penumbra, INC. | $9.96 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osman Mir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.